Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.62 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.62 |
| ▸ | NMT1 | P30419 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.44 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12128778 | 0.87 | HRH3 (0.66) | HRH3HRH4NMT1ACHE | |
| SCHEMBL3383793 | 0.87 | ATR (0.51) | HRH3HRH4 | |
| SCHEMBL2998111 | 0.81 | NMT1 (0.48) | HRH3HRH4NMT1ACHEMAP4K4 | |
| SCHEMBL1108663 | 0.81 | NMT1 (0.54) | HRH3HRH4NMT1ACHETLR7 | |
| SCHEMBL2320244 | 0.81 | NMT1 (0.51) | HRH3HRH4NMT1ACHEMAP3K11 | |
| SCHEMBL4520060 | 0.80 | ACHE (0.50) | HRH3HRH4NMT1ACHEMAP3K11 | |
| SCHEMBL1256229 | 0.80 | NMT1 (0.53) | HRH3HRH4NMT1ACHESIGMAR1 | |
| SCHEMBL14924463 | 0.80 | NMT1 (0.56) | HRH3HRH4NMT1ACHETLR7 | |
| SCHEMBL30639140 | 0.79 | HRH4 (0.45) | HRH3HRH4PTGS1 | |
| SCHEMBL11252790 | 0.79 | HRH4 (0.45) | HRH3HRH4PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| EP-1686130-B1 | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents | PFIZER PROD INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070161666-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2007-07-12 | — | — | US | disclosed |
| US-7192963-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1686130-A1 | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents | Pfizer Products Incorporated (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1294724-B1 | PYRROLO¬2,3-D|PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS | PFIZER PROD INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6962993-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050197349-A1 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. | 2005-09-08 | — | — | US | disclosed |
| US-6696567-B2 | INHIBITION OF PROTEIN KINASES OR JANUS KINASE 3; TREATING OR PREVENTING ORGAN TRANSPLANT REJECTION, XENO TRANSPLATION, LUPUS, MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS, PSORIASIS, TYPE I DIABETES OR VARIOUS DISEASE COMPLICATIONS | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030220353-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | HRH3 72/4885HRH4 71/4885NMT1 783/4885 |
| US-20030220353-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, CDK2, JAK3 | HRH3 2568/4885HRH4 2445/4885NMT1 3611/4885 |
| US-20050197349-A1 | Pyrrolo[2,3-D]pyrimidine compounds | CDK2, CDK3, JAK3 | HRH3 1620/4885HRH4 1812/4885NMT1 3955/4885 |
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, CDK2, JAK3 | HRH3 2568/4885HRH4 2445/4885NMT1 3611/4885 |
| US-20070161666-A1 | Pyrrolo[2,3-d]pyrimidine compounds | CDK2, CDK3, JAK3 | HRH3 1620/4885HRH4 1812/4885NMT1 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.